Imaging Characteristics of CNS Neuroblastoma-FOXR2: A Retrospective and Multi-Institutional Description of 25 Cases


ABSTRACT

BACKGROUND AND PURPOSE: The 5th edition of the World Health Organization Classification of CNS tumors defines the CNS neuroblastoma FOXR2 in the group of embryonal tumors. Published clinical outcomes tend to suggest a favorable outcome after resection, craniospinal irradiation, and chemotherapy. This multicenter study aimed to describe imaging features of CNS neuroblasto-
ma-FOXR2, which have been poorly characterized thus far.

MATERIALS AND METHODS: On the basis of a previously published cohort of tumors molecularly classified as CNS neuroblastoma-
FOXR2, patients with available imaging data were identified. The imaging features on preoperative MR imaging and CT data were recorded by 8 experienced pediatric neuroradiologists in consensus review meetings.

RESULTS: Twenty-five patients were evaluated (13 girls; median age, 4.5 years). The tumors were often large (mean, 115 [SD, 83] mL), showed no (24%) or limited (60%) perilesional edema, demonstrated heterogeneous enhancement, were often calcified and/or hemorrhagic (52%), were always T2WI-hyperintense to GM, and commonly had cystic and/or necrotic components (96%). The mean ADC values were low (687.8 [SD 136.3] × 10⁻⁶ mm²/s). The tumors were always supratentorial. Metastases were infrequent (20%) and, when present, were of nodular appearance and leptomeningeal.

CONCLUSIONS: In our cohort, CNS neuroblastoma FOXR2 tumors showed imaging features suggesting high-grade malignancy and, at the same time, showed characteristics of less aggressive behavior. There are important differential diagnoses, but the results of this study may assist in considering this diagnosis preoperatively.

ABBREVIATIONS: ATRT = atypical teratoid/rhabdoid tumors; CNS NB-FOXR2 = CNS neuroblastoma FOXR2-activated; CNS-PNET = primitive neuroecto-
dermal tumors of the CNS; ETMR = embryonal tumor with multilayered rosettes; ITD = internal tandem duplication; WHO = World Health Organization

In the recent 5th edition of the World Health Organization (WHO) Classification of CNS Tumors, published in 2021,¹ the CNS neuroblastoma FOXR2-activated (CNS NB-FOX2R) has been included as a new entity in the group of embryonal tumors that are highly malignant CNS tumors mainly occurring in children, adolescents, or young adults.² In the 2016 update of the WHO Classification, the embryonal tumors had emerged from the primitive neuroectodermal tumors of the CNS (CNS-PNET), which were replaced after an increasing number of molecular markers and genetic alterations had substantially advanced diagnostic specificity. In their important re-analysis of previously diagnosed CNS-PNET using DNA methylation profiles, Sturm et al³ were able to show that this group of tumors is highly heterogeneous, consisting of many known entities, eg, medulloblas-
toma, embryonal tumor with multilayered rosettes (ETMR), or atypical teratoid/rhabdoid tumors (ATRT) among others. In

Received March 28, 2022; accepted after revision July 27.

From the Institute of Neuroradiology (A.T.), Great Ormond Street Hospital, London, UK; Department of Pediatric Radiology (M.H.L.), University Hospital Augsburg, Augsburg, Germany; Department of Radiology (K.M., U.L.), Great Ormond Street Hospital, London, UK; Department of Pediatric Radiology (M.H.L.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Pediatric Radiology (L.I.), Queen Silvias Children’s Hospital of Chicago, Chicago, Illinois; Children’s Hospital Colorado, Denver, Colorado; Department of Medical Imaging (A.J.), Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Hopp Children’s Cancer Center (M.K.), Heidelberg, Germany; Division of Pediatric Neurooncology (M.K.), German Cancer Research Center and German Cancer Consortium, Heidelberg, Germany; Princess Maxima Center for Pediatric Oncology (M.K.), Utrecht, the Netherlands; and Department of Neuroradiology (B.B.), University Hospital Augsburg, Augsburg, Germany.

A. Tietze and K. Mankad shared first authorship.
B. Bison and U. Löbel shared last authorship.

This work was supported by the German Research Foundation (DFG, SFB295 RETUNE).

http://dx.doi.org/10.3174/ajnr.A7644

Indicates article with online supplemental data.
addition, DNA methylation analyses revealed several new tumor types in this group, one of which is the CNS NB-FOX2.

Available clinical data so far suggest that favorable rates of overall survival can be achieved for patients with CNS NB-FOX2 when treated with surgical resection, craniospinal irradiation, and chemotherapy. Imaging characteristics suggesting the diagnosis are currently based on the description of single patients, and to the best of our knowledge, larger series are not yet available. The reason is undoubtedly the increasingly detailed tumor classification, which results in a low incidence of confirmed cases in single centers and makes international collaboration essential to pool imaging data.

The aim of this article was to describe the imaging characteristics of CNS NB-FOX2 based on an international patient cohort and, at the same, establish a practical approach to collect and evaluate larger series across multiple centers.

MATERIALS AND METHODS

The cohort is based on a previously published cohort of pathology samples with the original diagnosis of CNS-PNET, which was subsequently molecularly reclassified as CNS NB-FOX2. This study was evaluated and approved by the ethics board of the coordinating institutions. Molecular diagnosis was confirmed by DNA methylation classification (Version 11b4 or higher; www.molecularneuropathology.org) in each included case. Informed consent was obtained by the patients or legal representatives at the time of the initial study or registry inclusion, or for some centers, the requirement for informed consent was waived. Imaging data for 2 of the cases have been published previously.

The image evaluation team consisted of at least 1 local neuroradiologist. Consensus decisions were made in joint online meetings on a weekly basis for 12 weeks regarding the following characteristics on pseudonymized images: 1) location, 2) cortical and/or WM involvement, 3) assumed tumor origin, 4) calvarial involvement, 5) approximation of volume (calculated \( \frac{\text{transverse} \times \text{craniocaudal} \times \text{anterior-posterior diameter}}{2} \)), 6) strength of enhancement compared with the choroid plexus (none, mild, intermediate, strong), 7) extent of enhancement (in categories: 0%, 0%–25%, 25%–50%, 50%–75%, 75%–100%, or 100% of the solid tumor component), 8) T2WI intensity compared with unaffected cortex, 9) susceptibility indicating calcification and/or hemorrhage on gradient-echo imaging (T2* or SWI, potentially further specified by CT, T1WI, T2WI), 10) average ADC_{minimum}, ADC_{mean}, ADC_{maximum} values (±SD), in an ROI, 0.14–0.65 cm² in size, in visually determined areas with the lowest values, 11) multifocality, 12) multilobulated appearance, 13) the presence/extent of perifocal edema (in categories: none, < 25% of the perimeter, 25%–75%, 100%), 14) the presence of nonsolid components (thin-walled cysts and/or necrotic regions defined as having irregular and thick borders), 15) extent of nonsolid components (in categories: 0%, 0%–25%, 25%–50%, 50%–75%, 75%–100%, or 100% of solid-to-entire tumor), 16) the presence and extent of ventricular system without normal tissue seen between the tumor and the ventricular wall. Often, the ventricular wall was infiltrated (64%; Fig 1A). In 60% of cases, the right hemisphere was affected. The WM was always infiltrated. In 80% of cases, there was also infiltration of the cortex, while in 20%, the cortex was merely compressed. Generally, we found it difficult to determine the origins of the tumors owing to their large sizes, but assuming that the epicenter of the tumor usually reflects the origin, 52% appeared to originate in the WM, and 32%, in the cortex. In only 8% of cases, did the tumors seem to originate from the deep GM and/or the WM of the internal capsule. None of the cases occurred in the brainstem or the infratentorial compartment.

Calvarial remodeling was found in 48%, associated with calvarial signal changes in 33%. The average tumor size was 115 (SD, 83) mL and was often larger in the 48% of cases with associated skull remodeling and scalloping (148 [SD, 87] mL) compared with cases without remodeling (85 [SD, 87] mL; Fig 1G).

In most cases, solid tumor components showed intermediate-but-inhomogeneous enhancement as well as peripheral enhancement of necrotic elements (Fig 1E, -F) or cyst walls. Dural infiltration was noted in 2 cases.

RESULTS

Patients

MR imaging data were available for 25 treatment-naïve patients (13 girls) with CNS NB-FOX2 diagnosed between 2003 and 2021. The median age was 4.5 years (interquartile range, 3.1–9 years; range, 1.4–16 years).

Imaging

MR imaging data consisted of T1WI, T2WI, FLAIR, and contrast-enhanced T1WI for all patients, gradient-echo imaging (T2* or SWI) for 14 patients, and DWI for 21 patients. Arterial spin-labeling PWI and single-voxel MRS (short TE) were available for 1 patient. All MR images were acquired before total/partial/subtotal tumor resection or treatment initiation. In a single patient, MR imaging was performed after the insertion of an external ventricular drain; all other patients were treatment-naïve. Four patients had a baseline CT scan.

Imaging Features

Results are summarized in the Online Supplemental Data, and representative imaging features in selected patients are shown in Fig 1. Further examples are available in the Online Supplemental Data, and all results are given as Online Supplemental Data. The brain regions most frequently affected were the frontal lobe (72%), followed by the parietal (44%) and temporal (36%) lobes, as well as the basal ganglia (32%). Typically, >1 region was involved. In most cases (80%), 1 or 2 anatomic compartments were involved, mostly the frontal lobe with or without the basal ganglia/thalami. In most cases, the tumor directly abutted the ventricular system without normal tissue seen between the tumor and the ventricular wall. Often, the ventricular wall was infiltrated (64%; Fig 1A). In 60% of cases, the right hemisphere was affected. The WM was always infiltrated. In 80% of cases, there was also infiltration of the cortex, while in 20%, the cortex was merely compressed. Generally, we found it difficult to determine the origins of the tumors owing to their large sizes, but assuming that the epicenter of the tumor usually reflects the origin, 52% appeared to originate in the WM, and 32%, in the cortex. In only 8% of cases, did the tumors seem to originate from the deep GM and/or the WM of the internal capsule. None of the cases occurred in the brainstem or the infratentorial compartment.

Calvarial remodeling was found in 48%, associated with calvarial signal changes in 33%. The average tumor size was 115 (SD, 83) mL and was often larger in the 48% of cases with associated skull remodeling and scalloping (148 [SD, 87] mL) compared with cases without remodeling (85 [SD, 87] mL; Fig 1G).

In most cases, solid tumor components showed intermediate-but-inhomogeneous enhancement as well as peripheral enhancement of necrotic elements (Fig 1E, -F) or cyst walls. Dural infiltration was noted in 2 cases.
Signal loss was noted in 43% of cases with available SWI or T2* data (Fig 1C). It was not possible to confidently determine the cause of increased susceptibility (hemorrhage versus calcification) even if phase images were available. However, in 3 patients, calcifications were unequivocally identified by CT, and in 1 patient, associated fluid levels confirmed the presence of hemorrhage on MR imaging. Altogether in 48% of cases, calcifications or hemorrhages or both were diagnosed on the basis of a combination of T1WI, T2WI, T2*, SWI, and the B₀ series of DWI data.

ADC values varied considerably between and within tumors (Fig 1D), but generally low values were probed in the solid portion, with an average ADCmean of 687.8 (SD, 136.3) × 10⁻⁶ mm²/s. Most tumors showed a multilobulated appearance (64%; Fig 1A–F), and 20% were multifocal. Perifocal edema was not particularly pronounced and, at most, of intermediate degree. Almost all tumors had nonsolid parts (Fig 1A, -B and E, -F) except the second smallest, which had a volume of only 10.5 mL. Unequivocal necrosis with thick, irregular, enhancing walls was diagnosed in 16% of cases (Fig 1A, -E); cysts, in 25%; and both, in another 25%.

Intracranial metastases were detected in 5 patients (20%), characterized by nodular leptomeningeal disease. One of these patients (a 4.5-year-old boy) also showed intraspinal dissemination.

High lipid and lactate peaks were noted in the enhancing part of the tumor with available MRS (single-voxel, short TE). Enhancing and nonenhancing tumor components showed a decrease in the NAA/Cr ratio (0.8 and 0.96, respectively) and an increase in Cho/NAA (3.12 and 1.74, respectively) and Cho/Cr (2.5 and 1.66, respectively) ratios. CBF was elevated on arterial spin-labeling data in the same patients.

The tumor of 1 patient, a 5-year-old boy presenting with seizures, was initially suspected to represent focal cortical dysplasia based on MR imaging findings (Fig 2A). He was treated for epilepsy under regular MR imaging surveillance. After 8 months, interval growth was noted (Fig 2B), prompting total resection. A CNS NB-FOXR2 tumor was diagnosed, whereas the diagnosis of a focal cortical dysplasia was dismissed.

DISCUSSION

CNS NB-FOXR2 has recently been added as a tumor type in the 2021 WHO Classification of CNS tumors. Therefore, only a few case series describing its imaging features exist.6,7,10-13 In our international cohort of 25 patients, we found that these were
supratentorial, often large, multilobulated tumors with little-or-no perifocal edema. Tumors nearly always showed a mix of solid and cystic/necrotic components. Involvement of the cortex was present in most cases, and the WM was involved in all patients. Lesions showed intermediate and inhomogeneous contrast enhancement and high vascularity with the presence of hemorhage and/or calcifications. The epicenter of the tumor appeared to be in the periventricular and subcortical WM or the cortex. In almost half of the cases, the adjacent skull was remodeled with thinning of the inner table, and in some cases, pathologic signal changes in the affected bone were present. The T2WI intensity in the solid parts was heterogeneous, but always hyperintense to GM. The ADC values were relatively low but fluctuated considerably within the solid components. Multifocality and dissemination were seen, but rarely.

CNS NB-FOXR2 tumors in our cohort showed several imaging features suggesting a high-grade malignancy, such as low ADC values, large volumes, and necrosis. However, they also showed characteristics of less aggressive tumors, including relative T2WI hyperintensity, little perifocal edema, and remodeling of the skull. Imaging characteristics described in our study are not specific, and ependymoma and other embryonal tumors such as ETMR, CNS tumor with BCOR internal tandem duplication (CNS BCOR-ITD), and ATRT need to be considered in the differential diagnosis. Of these tumors, CNS NB-FOXR2 is the only type that, to the best of our knowledge, has exclusively presented in a supratentorial location, whereas the other tumor types can develop infratentorially with varying frequencies.4,10,11,13-19 In addition, patient age may help with differentiation because the median age at diagnosis for patients with CNS NB-FOXR2 is 5 years (range, 1–20 years), while patients rarely present within the first 2 years of life.4 In contrast, patients with ATRT are typically younger than 2 years of age, with 33% younger than 1 year of age at diagnosis.20 ETMR usually presents in the first 4 years of life,4,21,22 and the median age for presentation with CNS BCOR-ITD is 4 years (range, 0.6–22 years). The presentation age for supratentorial ependymomas is highly dependent on the molecular subtype. Supratentorial ependymoma, YAP1 fusion–positive, occurs at a median age of 1.4 years,23 while ZFTA fusion–positive ependymoma presents at a median age of 8 years (largely overlapping with tumors previously diagnosed as ependymoma, RELA-fused).23,24

The discrepancy between restricted diffusion, usually attributed to high cellularity, and high signal on T2WI that is typically seen in low-proliferative processes has previously been described in ATRT.14 High cellularity is, however, only one of several causes for restricted diffusion. The microenvironment, neuropil density, cell size, or nuclear volume fraction may contribute to low ADC values, possibly without necessarily decreasing the T2WI signal.25 With the current data, we are not able to specify these contributions in more detail. Skull remodeling was found in nearly half of our patients. While this is a relatively common feature in low-grade CNS tumors, we found additional calvarial signal changes in some of these cases, which has also been described at initial diagnosis in ATRT19 but appears to be rare in other pediatric high-grade tumors.

Only 1 previously published case can be compared with our series7 because the 2 patients described previously by Holsten et al6 are included in our cohort. However, because the focus of the case report by Furuta et al7 was not primarily on imaging characteristics, the comparison remains limited. Furuta et al also found a relatively large, partially enhancing, centrally necrotic tumor with scattered calcification but, in their case, with extensive perilesional edema.

As stated previously, some of the cases we included represent a subcohort of a previously published pathology series of retrospectively re-classified CNS NB-FOXR2 tumors.4 In this study of 307 tumors with an initial diagnosis of CNS-PNET, 36 (12%) were classified as CNS NB-FOXR2 by DNA methylation profiling in this series. In a pooled cohort of 63 patients with CNS NB-FOXR2, which included additionally identified cases, the 5-year progression-free survival and overall survival was 63% and 85%.5 The frequency of relapses was lowest among patients treated with surgical resection and craniospinal irradiation combined with chemotherapy. This finding is in agreement with another published series that includes overlapping patients.5

We did not use the Visually Accessible Rembrandt Images (VASARI) criteria26 for our assessments because the criteria were not judged fit for our purpose, too detailed in some respects, and not pediatric-specific.

Due to the retrospective nature of our study, the imaging data were sometimes incomplete (eg, missing DWI and T2*/SWI series). While CT images were especially helpful in verifying calcifications or bony changes, they were only available for 4 patients. In addition, advanced MR imaging may have been useful to characterize the tumors in more detail, eg, by shedding some light on neo-angiogenesis with PWI or on metabolic and microstructural changes by MRS or advanced diffusion-weighted techniques, but the multi-institutional approach and the long inclusion period of >18 years due to the rarity of these tumors precluded the availability of these imaging techniques in this study.

The integrated diagnosis of molecular and morphologic features in CNS tumor diagnostics has radically changed the classification system. The knowledge of an increasing number of molecular profiles and the revision of previous classification groups has entailed and will entail a far more detailed taxonomy. Multicenter collaboration becomes pivotal as cases become rarer, and tumor entities will have to be phenotyped through consensus reading. Our experience with weekly joint online meetings was excellent to achieve this objective.

CONCLUSIONS

We described typical imaging characteristics of CNS NB-FOXR2 tumors in a multicenter series of 25 patients, the largest to date. Our findings contribute further to the description of new tumor types included in the 5th edition of the WHO Classification of CNS tumors. Important work lies ahead of radiologists to describe and possibly differentiate these emerging entities. Because an increasing subdivision will inevitably be accompanied by fewer cases per center, further multi-institutional reviews will be needed in the future.

ACKNOWLEDGMENTS

We thank Magnus Sabel and Elizabeth Schepke (Queen Silvias Children’s Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden), Stefan Rutkowski (Department of Paediatric Haematology

and Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany), Barbara von Zeschwitz (Department of Pediatric Oncology and Hematology, Charité–Universitätsmedizin Berlin, Germany), Darren Hargrave (Pediatric Oncology Unit, UCL Great Ormond Street Institute of Child Health, London, UK), Tom Jacques (Developmental Biology and Cancer Research & Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK), and Pieter Wesseling (Department of Pathology, Amsterdam University Medical Centers/VU Medisch Centrum, Amsterdam, the Netherlands) for contributing clinical and molecular data. All research at Great Ormond Street Hospital NHS Foundation Trust and UCL Great Ormond Street Institute of Child Health is made possible by the NIHR Great Ormond Street Hospital Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES


20. WHO Classification of Tumours Editorial Board. Central Nervous System Tumours: Who Classification of Tumours. 5th ed. International Agency for Research on Cancer; December 2021


